Persistent genital arousal disorder (PGAD): a rare and under-recognised condition

Overview

Persistent Genital Arousal Disorder (PGAD) is a rare, under-recognised condition first described in 2001 by Leiblum and Nathan in a case series of five women. In 2006, Leiblum revised the terminology from "Persistent Sexual Arousal Syndrome" (PSAS) to "Persistent Genital Arousal Disorder" (PGAD), to better reflect the disorder's core symptom—persistent genital arousal—occurring independently of sexual desire or activity.

PGAD primarily affects women and can emerge across a wide age range. It is often compared to priapism in men due to its hallmark feature: unrelenting and intrusive genital arousal. Individuals experience spontaneous, persistent, involuntary genital arousal not triggered by sexual stimuli, often without visible signs such as swelling or orgasm. 

Despite its distressing nature, PGAD remains poorly understood, with no clearly identifiable hormonal, neurological, vascular, or psychological causes. The condition can severely impact quality of life, frequently leading to emotional distress, mood disorders, cognitive distortions such as catastrophizing, social withdrawal, and, in some cases, suicidal ideation.

Epidemiology and diagnostic challenges

The low incidence of Persistent Genital Arousal Disorder (PGAD) in clinical literature is likely due to patient reluctance to disclose symptoms and frequent misdiagnosis. Social stigma, embarrassment, and limited provider awareness contribute to underreporting of the condition. While surveys have identified many cases, its true prevalence remains uncertain. 

Research is limited, but studies suggest PGAD may affect 0.6% to 3% of women globally. For example, a London sexual health clinic found that 1% of women met diagnostic criteria for PGAD, while 3.1% reported genital arousal without distress.⁵ A Canadian study among university students found that 0.6% of female participants reported similar symptoms.

PGAD may be constant or episodic, with some experiencing lifelong symptoms and others developing them around age 37. Notably, about 25% of cases begin before age 18, underscoring the need for broader clinical awareness.

Pathophysiology

The pathophysiology of Persistent Genital Arousal Disorder (PGAD) remains poorly understood, a result of the complex interplay of biological, psychological and social factors. Contributing elements include psychological tendencies like catastrophising, medical conditions such as pudendal nerve dysfunction or spinal abnormalities, and pharmacological factors like SSRI withdrawal. Social factors, including lack of awareness and stigma, further complicate the condition. 

Clinical studies suggest a neurological basis with research showing that women with PGAD exhibit heightened activity in the somatosensory cortex, particularly the paracentral lobule, even without genital stimulation, indicating a potential neurological origin.

Comparison of brain activity in patients experiencing PGAD/GPD symptoms and those with no PGAD/GPD. While varying biopsychosocial etiologies may contribute to PGAD/GPD, there is likely a common underlying neurobiological basis within the brain that accounts for symptoms associated with an intense, unwanted genito-pelvic sensory activity. Panel A: Functional magnetic resonance image (fMRI) acquired in a human volunteer who was experiencing active PGAD/GPD symptoms. Panel B: fMRI in a healthy human volunteer without PGAD/GPD who was thinking about clitoral stimulation in the absence of any physical stimulation. Relative intensity of activation is shown by a representative pseudo-colour hot metal analogue scale, where dark red is least intense, orange/yellow is intermediate, and white is most intense. The sensory thalamus (TH) and secondary sensory cortex (S2), unilaterally or bilaterally, are also activated under these conditions, as shown in the fMRI images.

Persistent genital arousal disorder (PGAD): clinical presentation and psychological impact

PGAD/GPD starts with mild genital awareness, progressing to severe symptoms like genital pain, clitorodynia, painful intercourse, and bladder or bowel dysfunction. Some may experience spontaneous orgasms or ejaculation. Symptoms can be constant, intermittent, or fluctuating and may develop gradually or suddenly. 

A detailed medication history is important, as certain drugs, especially SSRIs, are linked to acquired PGAD/GPD. Psychological impacts include anxiety, depression, and suicidal ideation, requiring mental health assessments. 

Differential diagnosis is crucial to distinguish PGAD/GPD from conditions like hypersexuality or CSBD. Common comorbidities include pelvic floor dysfunction, pudendal nerve neuropathy, and lumbar issues. 

Diagnostic criteria involve persistent, unwelcome arousal not linked to sexual desire, triggered by both sexual and nonsexual stimuli, with orgasm offering only temporary relief.

Role of antidepressants, anticonvulsants, and anaesthetics in PGAD treatment

The treatment of PGAD is challenging due to its unclear etiology and pathophysiology. Various medications have been used to manage symptoms, including antidepressants, anticonvulsants, and anaesthetics.

Role of serotonin reuptake inhibitors in PGAD treatment

The exact etiology of PGAD remains uncertain, but research has suggested that antidepressants, particularly those with serotonergic activity, play a complex and dual role in its manifestation and management.

Antidepressants as a treatment for PGAD

Certain antidepressants, particularly those with serotonergic and noradrenergic activity, have been explored as treatment options for Persistent Genital Arousal Disorder (PGAD). By modulating neurotransmitter levels and influencing central arousal pathways, some of these medications have shown potential in alleviating PGAD symptoms.

Among SSRIs, paroxetine has been the most studied, with daily doses of 20–30 mg showing benefits in alleviating spontaneous orgasms and reducing genital arousal. However, results are mixed—some studies report only partial relief, while others find no significant improvement.

The SNRI duloxetine has shown promise in reducing genital sensitivity, masturbation urges, and genital pain. It may be particularly useful for PGAD patients with coexisting anxiety or depression. Some individuals with PGAD secondary to Tarlov cysts have also reported partial symptom relief with duloxetine, although broader clinical efficacy remains limited.

Tricyclic antidepressants and combination therapies

Clomipramine, a tricyclic antidepressant (TCA) with strong serotonergic properties, has been used in PGAD treatment at doses of 75–150 mg/day. It acts on the hypothalamus and limbic system, key centers regulating female sexual arousal. Case reports suggest success when clomipramine is used alone or in combination with fluoxetine and clonazepam.

In one notable regimen, clomipramine (150 mg/day), fluoxetine (40 mg/day), and clonazepam were used together, followed by leuprolide injections, resulting in significant symptom improvement.

Other antidepressants and experimental approaches

Other medications, including venlafaxine (150 mg/day), sertraline (200 mg/day), escitalopram (10 mg/day), and citalopram (20 mg/day), have also been tried, though they generally yield inconsistent or minimal symptom relief.

Interestingly, tramadol, an opioid analgesic with SNRI-like properties, has shown benefit in some cases. In one example, a 32-year-old woman with bipolar disorder developed PGAD symptoms after her venlafaxine dose was increased to 300 mg/day; symptoms resolved after the dose was reduced—indicating a possible dose-dependent effect.

Role of anticonvulsants in PGAD treatment

Anticonvulsants play a crucial role in managing Persistent Genital Arousal Disorder (PGAD) by regulating nerve activity and reducing sensory overstimulation. These medications target abnormal neural excitability, which is believed to contribute to the persistent symptoms of PGAD. As standardized treatment guidelines are lacking, more clinical research is needed to better understand the mechanisms of PGAD and optimize pharmacological strategies.

Among the anticonvulsants used for PGAD, Pregabalin and Carbamazepine have shown promise in modulating sensory nerve excitability. Commonly used for neuropathic pain, these drugs have the ability to regulate abnormal nerve signaling which has been beneficial for some PGAD patients. Pregabalin has shown effectiveness in reducing nerve hyperactivity linked to PGAD.

Clonazepam, a benzodiazepine with both anticonvulsant and GABA-A receptor agonist properties, has been found to be effective in approximately 56% of PGAD cases. By enhancing GABAergic inhibition, Clonazepam helps dampen nerve hyperexcitability, leading to symptom relief. Its mechanism of action is similar to its role in treating Restless Leg Syndrome (RLS), another condition involving excessive nerve activity. The recommended dosage typically ranges between 0.5 mg and 1.5 mg per day.

Carbamazepine, administered at 600 mg/day, has also been explored as a treatment option, though its effectiveness appears limited—possibly due to inconsistent adherence. While some patients report symptom relief, its overall benefit in PGAD management remains uncertain.

Bupropion, an atypical antidepressant with dopaminergic and noradrenergic effects, has shown potential, particularly when combined with psychological therapy. This combination may benefit individuals with PGAD who have a history of trauma or sexual abuse. Bupropion's ability to influence dopamine levels may help regulate sexual arousal responses in affected individuals.

Recent neurological research has highlighted the role of epileptic activity and functional brain connectivity in PGAD. In one study, a woman with PGAD and orgasmic seizures was found to have an epileptic focus in the left posterior insular gyrus (LPIG)—a region involved in sensory processing and autonomic function. Using EEG, MEG, and fMRI, researchers observed increased functional connectivity between the LPIG and other brain areas, indicating a complex neural network associated with PGAD. After long-term treatment with the antiepileptic topiramate (300 mg/day), the patient’s PGAD symptoms resolved. Follow-up neuroimaging showed reduced functional connectivity, especially in the left hemisphere, supporting the role of anticonvulsants in normalizing brain activity and alleviating symptoms in neurologically linked PGAD.

Role of anaesthetics in PGAD treatment

Local anaesthetics, including benzocaine, lidocaine, and tetracaine, play a significant role in the temporary relief of PGAD symptoms by numbing the affected areas and reducing heightened genital sensations. These anaesthetics are especially useful in cases where PGAD symptoms are linked to vestibular erythema, a condition that causes inflammation of the vestibule, or when nerve dysfunction and increased pelvic floor muscle tone are contributing to the disorder.

One illustrative case involved a woman in her early 40s who developed persistent genital arousal and bladder discomfort after sustaining a pelvic injury from a horseback riding accident. Despite undergoing numerous evaluations, such as imaging, cystoscopies, urodynamic tests, and various pharmacological and physical treatments, her symptoms continued unabated. A thorough physical examination revealed high pelvic floor muscle tone and sensitivity in the pudendal nerve, confirming PGAD triggered by pudendal nerve irritation.

She underwent a bilateral pudendal nerve block using lidocaine, which resulted in over 50% symptom relief. This was followed by corticosteroid injections, leading to sustained improvement. Given the positive response, her care team considered additional interventions, including botulinum toxin injections, for long-term management. Regular follow-ups were scheduled to monitor her progress and modify the treatment plan as needed.

This case highlights the effectiveness of anaesthetic-based treatments, particularly when nerve irritation and pelvic muscle dysfunction are central to PGAD symptoms. 

Furthermore, in another recent case, three young women diagnosed with PGAD, in whom vestibular erythema was identified through vulvoscopy, benefited from vestibular anaesthesia. This involved applying a combination of topical anaesthetics—20% benzocaine, 8% lidocaine, and 6% tetracaine—at specific sites, including the lateral Hart’s line and the medial hymenal region. ¹ The treatment led to effective symptom alleviation, underscoring the potential of targeted anaesthetic interventions in PGAD management.

Summary

Persistent Genital Arousal Disorder (PGAD) is a complex, under-recognized condition affecting up to 3% of women, with no FDA-approved treatments. Management involves off-label medications like SSRIs, anticonvulsants, and anaesthetics, though effectiveness varies. Lack of controlled studies complicates treatment. Physical and psychological therapies are also key. A holistic, multidisciplinary approach and more research are needed to improve patient outcomes.